ArticleJournal of medical case reports2026
Advances in the management of osteopenia: a case series.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteopenia is a pre-pathological condition characterized by reduced bone mineral density that may lead to increased fracture risk and to the onset of osteoporosis. Standard treatments for managing osteopenia include supplementation of calcium, vitamin D, and vitamin K. Interestingly, recent studies suggest D-chiro-inositol and α-lactalbumin may enhance bone health through mechanisms such as insulin sensitization and improved nutrient absorption; furthermore, D-chiro-inositol is thought to be a specific mediator of osteoclast activity by inhibiting the expression of several osteoclastogenic genes. CASE PRESENTATION: Six Caucasian patients with osteopenia-four men and two women with an average age of about 41 years-were treated with a daily regimen of calcium (400 mg), cholecalciferol (50 μg), vitamin K2 (50 μg), D-chiro-inositol (150 mg), and α-lactalbumin (30 mg) for 2 months. Even though the results reported no significant changes in T-score value, all patients exhibited improved serum levels of vitamin D and osteocalcin, along with fluctuations in alkaline phosphatase and parathyroid hormone levels.
conclusionDespite the preliminary nature of the obtained data, combined supplementation exerted positive effects on bone metabolism by influencing serum levels of both vitamin D and osteocalcin, thus suggesting enhanced bone formation. Biochemical improvements support the potential of D-chiro-inositol and α-lactalbumin, in addition to traditional supplements, as a therapeutic strategy for managing osteopenia, even though further clinical studies are needed to clarify the effects and related molecular mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.